A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects

Inclusion Criteria: 1. Age ≥ 18 years, gender not restricted; 2. Estimated survival time ≥ 3 months; 3. Confirmed diagnosis of gastrointestinal tumors by pathological examination, including esophageal cancer, gastric cancer, colon cancer, rectal cancer, etc.; 4. TNM staging of cancer in patients is Stage IV; 5. Having undergone PD-1 or PD-L1 testing; 6. Planned to receive the 4th cycle of chemotherapy/targeted therapy; 7. Occurrence of gastrointestinal adverse reactions (including but not limited to diarrhea, constipation, vomiting, nausea, etc.) within 3 cycles of conventional chemotherapy/targeted therapy; 8. Patients are able and willing to sign the informed consent form and complete follow-up; 9. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 1-3; 10. Use of oral/intravenous broad-spectrum antibiotics with caution within 3 days; 11. Patients are able to swallow capsules without chewing; 12. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 1-3; 13. Laboratory test results during the screening period indicate that the subjects have sufficient organ function. Exclusion Criteria: 1. Patients with major organ dysfunction or even failure, including but not limited to cardiac insufficiency or heart failure, renal insufficiency or renal failure, and hepatic insufficiency/hepatic failure; 2. Uncontrolled or severe infections; 3. Known history of psychotropic substance abuse, alcoholism, and drug abuse; 4. Patients with severe infections complicated with septicemia or sepsis; 5. Patients with a history of severe allergic reactions or a known allergy to the components of liquid live bacteria enteric-coated capsules; 6. Patients with active viral infections; 7. Female subjects with a positive pregnancy test, lactating female subjects, and women of childbearing age who refuse to use contraceptive measures during the entire observation period (15 weeks); 8. Patients with gastrointestinal perforation and/or fistula; 9. Other conditions deemed unsuitable for enrollment by the investigator.